Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
49.05
+0.59 (1.22%)
Aug 13, 2025, 4:00 PM - Market closed
PRAX Employees
Praxis Precision Medicines had 116 employees as of December 31, 2024. The number of employees increased by 34 or 41.46% compared to the previous year.
Employees
116
Change (1Y)
34
Growth (1Y)
41.46%
Revenue / Employee
$66,940
Profits / Employee
-$2,163,897
Market Cap
1.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116 | 34 | 41.46% |
| Dec 31, 2023 | 82 | -27 | -24.77% |
| Dec 31, 2022 | 109 | -30 | -21.58% |
| Dec 31, 2021 | 139 | 72 | 107.46% |
| Dec 31, 2020 | 67 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRAX News
- 15 hours ago - PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 7 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewsWire
- 8 days ago - Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 9 days ago - Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 3 months ago - Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga